Complete response of leptomeningeal carcinomatosis secondary to breast cancer

Leptomeningeal carcinomatosis (LC) is an unmet medical need associated with death in 4–6 weeks without treatment, delayed by 4 months in some patients with favorable prognosis and aggressive multimodal therapy. Unfortunately, most clinical trials excluded patients with LC, and the best management re...

Descripción completa

Detalles Bibliográficos
Autores principales: Troussier, Idriss, Canova, Charles, Klausner, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Viewpoints and Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718154/
https://www.ncbi.nlm.nih.gov/pubmed/33278649
http://dx.doi.org/10.1016/j.breast.2020.11.019
_version_ 1783619454010130432
author Troussier, Idriss
Canova, Charles
Klausner, Guillaume
author_facet Troussier, Idriss
Canova, Charles
Klausner, Guillaume
author_sort Troussier, Idriss
collection PubMed
description Leptomeningeal carcinomatosis (LC) is an unmet medical need associated with death in 4–6 weeks without treatment, delayed by 4 months in some patients with favorable prognosis and aggressive multimodal therapy. Unfortunately, most clinical trials excluded patients with LC, and the best management remains unknown. Here we present the first report of a LC secondary to HR positive breast cancer with a complete response to CDK4/6 inhibitors abemaciclib, letrozole and hippocampal-avoidance whole-brain radiotherapy.
format Online
Article
Text
id pubmed-7718154
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-77181542020-12-09 Complete response of leptomeningeal carcinomatosis secondary to breast cancer Troussier, Idriss Canova, Charles Klausner, Guillaume Breast Viewpoints and Debate Leptomeningeal carcinomatosis (LC) is an unmet medical need associated with death in 4–6 weeks without treatment, delayed by 4 months in some patients with favorable prognosis and aggressive multimodal therapy. Unfortunately, most clinical trials excluded patients with LC, and the best management remains unknown. Here we present the first report of a LC secondary to HR positive breast cancer with a complete response to CDK4/6 inhibitors abemaciclib, letrozole and hippocampal-avoidance whole-brain radiotherapy. Elsevier 2020-11-28 /pmc/articles/PMC7718154/ /pubmed/33278649 http://dx.doi.org/10.1016/j.breast.2020.11.019 Text en © 2020 Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Viewpoints and Debate
Troussier, Idriss
Canova, Charles
Klausner, Guillaume
Complete response of leptomeningeal carcinomatosis secondary to breast cancer
title Complete response of leptomeningeal carcinomatosis secondary to breast cancer
title_full Complete response of leptomeningeal carcinomatosis secondary to breast cancer
title_fullStr Complete response of leptomeningeal carcinomatosis secondary to breast cancer
title_full_unstemmed Complete response of leptomeningeal carcinomatosis secondary to breast cancer
title_short Complete response of leptomeningeal carcinomatosis secondary to breast cancer
title_sort complete response of leptomeningeal carcinomatosis secondary to breast cancer
topic Viewpoints and Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718154/
https://www.ncbi.nlm.nih.gov/pubmed/33278649
http://dx.doi.org/10.1016/j.breast.2020.11.019
work_keys_str_mv AT troussieridriss completeresponseofleptomeningealcarcinomatosissecondarytobreastcancer
AT canovacharles completeresponseofleptomeningealcarcinomatosissecondarytobreastcancer
AT klausnerguillaume completeresponseofleptomeningealcarcinomatosissecondarytobreastcancer

Ejemplares similares